Omgeo acquires Allustra for collateral management

"When we looked at the evolution of the buy side over the past five years, we saw that there was a gap in automation around collateral and how firms administer their OTC derivatives portfolios," explains Tim Lind, managing director of strategic planning at Omgeo.

According to Lind, it was preferable to make an acquisition rather than build collateral management functionality because of the speed at which the market is evolving.

Allustra was selected as it was "more suited to a buy-side

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: